Success Metrics

Clinical Success Rate
89.1%

Based on 106 completed trials

Completion Rate
89%(106/119)
Active Trials
9(6%)
Results Posted
53%(56 trials)
Terminated
13(9%)

Phase Distribution

Ph phase_1
17
12%
Ph not_applicable
13
9%
Ph early_phase_1
2
1%
Ph phase_3
40
28%
Ph phase_4
38
26%
Ph phase_2
33
23%

Phase Distribution

19

Early Stage

33

Mid Stage

78

Late Stage

Phase Distribution143 total trials
Early Phase 1First-in-human
2(1.4%)
Phase 1Safety & dosage
17(11.9%)
Phase 2Efficacy & side effects
33(23.1%)
Phase 3Large-scale testing
40(28.0%)
Phase 4Post-market surveillance
38(26.6%)
N/ANon-phased studies
13(9.1%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

86.2%

106 of 123 finished

Non-Completion Rate

13.8%

17 ended early

Currently Active

9

trials recruiting

Total Trials

144

all time

Status Distribution
Active(12)
Completed(106)
Terminated(17)
Other(9)

Detailed Status

Completed106
Terminated13
unknown9
Recruiting8
Withdrawn4
Not yet recruiting3

Development Timeline

Analytics

Development Status

Total Trials
144
Active
9
Success Rate
89.1%
Most Advanced
Phase 4

Trials by Phase

Early Phase 12 (1.4%)
Phase 117 (11.9%)
Phase 233 (23.1%)
Phase 340 (28.0%)
Phase 438 (26.6%)
N/A13 (9.1%)

Trials by Status

recruiting86%
withdrawn43%
terminated139%
not_yet_recruiting32%
active_not_recruiting11%
unknown96%
completed10674%

Recent Activity

Clinical Trials (144)

Showing 20 of 144 trialsScroll for more
NCT07715448Phase 4

Effect of Different Dosing Regimens of Tadalafil or Tamsulosin Combined With 5α-Reductase Inhibitors on Urinary and Sexual Outcomes in Benign Prostatic Hyperplasia

Completed
NCT07690566Not Applicable

Ultrasonic Enhancement Delivery of Phosphodiesterase Inhibitors Nanoparticles for Diabetic Management of the Foot

Completed
NCT07654413Phase 4

Tamsulosin With or Without Tadalafil for Trial Without Catheter After Acute Urinary Retention Due to Benign Prostatic Hyperplasia

Recruiting
NCT07642505Phase 4

L-Citrulline and Tadalafil for Mild to Moderate Erectile Dysfunction

Recruiting
NCT07636161Phase 4

PLEASURE (Pleasing Lovers, Efficacy, Arousal, Satisfaction, and Uptake Research on Eroxon)

Not Yet Recruiting
NCT07602608Phase 4

Platelet-Rich Plasma With or Without Tadalafil for Erectile Dysfunction

Completed
NCT06290713Phase 2

Vasodilator and Exercise Study for DMD (VASO-REx)

Recruiting
NCT05937854Phase 2

Breathe Easier With Tadalafil Therapy for Dyspnea in COPD-PH

Recruiting
NCT07245680Phase 3

COMMODITIES Trial: Initial Dual Oral Therapy vs Monotherapy in PAH With Cardiovascular Comorbidities

Recruiting
NCT05014776Phase 2

Study of CRS-207, Pembrolizumab, Ipilimumab, and Tadalafil in Metastatic Pancreatic Cancer

Completed
NCT03785210Phase 2

Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic Cancers

Terminated
NCT03993353Phase 2

Tadalafil and Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer

Completed
NCT05844462Phase 3

Tadalafil for Severe Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease

Recruiting
NCT07312955Not Applicable

Solifenacin Plus Tadalafil vs Solifenacin Alone for Overactive Bladder in Females

Completed
NCT05206955Phase 3

Study of Tadalafil vs. Placebo for Improving Hemodynamics and End-Organ Dysfunction in Fontan Physiology

Recruiting
NCT07172815Phase 2

PDE5 Inhibitor for Alzheimer's Disease

Not Yet Recruiting
NCT06968962Not Applicable

Comparison of Sequential to Initial Combination Therapy in PAH

Recruiting
NCT03238365Early Phase 1

Window of Opportunity Trial of Nivolumab and Tadalafil in Patients With Squamous Cell Carcinoma of the Head and Neck

Completed
NCT02558231Phase 3

The Efficacy and Safety of Initial Triple Versus Initial Dual Oral Combination Therapy in Patients With Newly Diagnosed Pulmonary Arterial Hypertension

Completed
NCT04235270Phase 1

A Study of Macitentan and Tadalafil as a Fixed Dose Combination and the Free Combination in Healthy Adult Participants

Completed

Drug Details

Intervention Type
DRUG
Total Trials
144